Clinical trial
Bisphosphonate Treatment of Osteogenesis Imperfecta
NCT00063479 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00063479 |
|---|---|
| Title | Bisphosphonate Treatment of Osteogenesis Imperfecta |
| Official title | Bisphosphonate Treatment of Osteogenesis Imperfecta |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Osteogenesis Imperfecta |
| Intervention type | Drug |
| Interventions | Zoledronic Acid |
| Enrollment | 158 |
| Start date | Jun 1, 2003 |
| Primary completion | May 1, 2007 |
| Completion | May 1, 2007 |
| First posted | Jun 30, 2003 |
| Last update posted | Jun 1, 2017 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: